Valuation: Black Diamond Therapeutics, Inc.

Market Cap 109M 97.02M 88.97M 80.86M 152M 10.29B 155M 1.06B 426M 5.45B 409M 400M 17.25B P/E 2026 *
-3.08x
P/E 2027 * -1.99x
Enterprise Value 109M 97.02M 88.97M 80.86M 152M 10.29B 155M 1.06B 426M 5.45B 409M 400M 17.25B EV / Sales 2026 *
17.4x
EV / Sales 2027 * -
Free-Float
99.34%
Yield 2026 *
-
Yield 2027 * -
1 day+4.97%
1 week+3.83%
Current month+6.74%
1 month+0.53%
3 months+6.74%
6 months-29.63%
Current year-21.81%
1 week 1.75
Extreme 1.75
1.96
1 month 1.6
Extreme 1.6
2.14
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
8.71
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 2023-09-15
Chief Tech/Sci/R&D Officer 51 2021-08-10
Director of Finance/CFO 41 2024-10-06
Director TitleAgeSince
Director/Board Member 61 2017-02-28
Director/Board Member 47 2019-11-30
Director/Board Member 49 2018-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/18/26 Free

Director

7,707 0.0134%
9/18/26 Free

Director

6,801 0.0118%
9/18/26
NEA Management Co. LLC
OtherCompany 0 0% -
Change 5-day change 1-year change 3-year change Capi.($)
+4.97%+3.83%-47.51%0.00% 104M
+10.00%+4.50%+58.63%+71.20% 60.57B
+1.44%+5.05%+22.52%+101.03% 55.51B
+3.32%+2.31%+11.04%+75.04% 55.22B
+0.46%-5.47%+25.04%+33.77% 43.27B
+2.82%+5.82%+240.96%+801.17% 41.63B
+6.42%+1.18%+22.18%+105.56% 40.36B
-3.79%-7.50%+89.46%+77.13% 33.29B
+5.32%+5.37%+19.12%+52.98% 32.27B
+5.32%+13.43%-39.82%+342.66% 22.91B
Average +3.63%+5.76%+40.16%+166.05% 38.51B
Weighted average by Cap. +3.72%+4.85%+52.19%+169.47%

Financials

2026 *2027 *
Net sales 6.25M 5.57M 5.11M 4.64M 8.73M 591M 8.92M 61.04M 24.47M 313M 23.46M 22.96M 990M -
Net income -36.96M -32.94M -30.21M -27.45M -51.6M -3.49B -52.78M -361M -145M -1.85B -139M -136M -5.86B -64.65M -57.61M -52.83M -48.01M -90.26M -6.11B -92.32M -631M -253M -3.23B -243M -237M -10.24B
Net Debt - -
Projected Income Statement - Annual - Black Diamond Therapeutics, Inc.
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
26-11-04 US$1.900 +4.97% 607,554
26-11-03 US$1.810 +3.43% 332,019
26-11-02 US$1.750 -1.69% 494,374
26-10-30 US$1.780 -4.30% 520,157
26-10-29 US$1.860 +1.64% 551,014
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Black Diamond Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.895USD
Average target price
10.00USD
Spread / Average Target
+427.70%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Black Diamond Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. BDTX Stock